Corbus Pharmaceuticals Holdings CRBP
NASDAQ CRBP
$4.00 +0.07 (+1.78%)
At close: Nov 11, 2026 · 4:00 PM EST

Corbus Pharmaceuticals Holdings (CRBP) Net Income Attributable to Noncontrolling Interests (2023 - 2024)

Updated

Analysis

Corbus Pharmaceuticals Holdings (CRBP) Net Income Attributable to Noncontrolling Interests (2023 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCI Net Income (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 2.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 2.00 Mn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -1.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 10.00 Mn
10 Corbus Pharmaceuticals Holdings 80.98 Mn -453.78 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -172,000.00
Sep 30, 2024 595,000.00
Dec 31, 2023 6,000.00
Sep 30, 2023 16,000.00
API Access

Corbus Pharmaceuticals Holdings Net Income Attributable to Noncontrolling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=CRBP&period=max&api_key=YOUR_API_KEY